Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418463

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps NHS England takes to assess the health and social care needs of patients with hidradenitis suppurativa; and what assessment he has made of the ability of the NHS to deliver efficient diagnosis and access to specialist care for such patients.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	10010
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.</p><p> </p><p> </p><p> </p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.</p><p> </p><p> </p><p> </p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found by viewing the specialised dermatology service specification at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10011 question first answered 16/09/2015 11:46:53 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

418464

registered interest
date	11/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress has been made by NHS England on the production of a commissioning policy for treatments associated with hidradenitis suppurativa; what the proposed scope of that policy is; and when he expects that policy to have been fully developed.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	10011
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>NHS England works in partnership with local commissioners and providers to ensure people with long-term conditions, such as hidradenitis suppurativa (HS), are supported to live healthily and independently and are empowered to take better control over the care they receive.</p><p> </p><p> </p><p> </p><p>The majority of patients with HS can be managed through routine access to primary and secondary care, including dermatology clinics, which is responsibility of the local National Health Service commissioners. Treatment and management of the condition involves antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe.</p><p> </p><p> </p><p> </p><p>For those patients with the more serious forms of HS, referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions, including HS, and has set out what providers must have in place in order to offer specialist dermatology care. This supports equity of access to a high quality service for patients wherever they live. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found by viewing the specialised dermatology service specification at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 10010 question first answered 16/09/2015 11:46:53 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

418471

registered interest
date	11/09/2015
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Company Investigations: Freezing of Assets
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, whether Sussex Police are required to freeze the assets of a company they are investigating; on what grounds police may freeze the assets of a company they are investigating; and at what point such assets may be unfrozen if police bail has expired and no charges have been brought.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9976
answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The Proceeds of Crime Act 2002 permits an application for a restraint order to be made to “freeze” assets of an alleged offender, which includes a company, if there is reasonable cause to suspect that an offender has benefitted from their criminal conduct. A restraint order has the effect of freezing property that may be liable to confiscation following a trial and the subsequent making of a confiscation order. There is no legal requirement for a police force to freeze the assets of a company they are investigating, although it is good practice to do so in cases in which assets need to be preserved for confiscation at a later date. A restraint order may be made by a Crown Court if any of the following conditions are satisfied:</p><p>(1) A criminal investigation has been started in England and Wales and there is reasonable grounds to suspect that the alleged offender has benefitted from criminal conduct</p><p>(2) Proceedings for an offence have been commenced in England and Wales and not concluded and there is reasonable grounds to believe that an alleged offender has benefitted from criminal conduct.</p><p>In addition to the statutory conditions, there must be a real risk that the assets will be dissipated.</p><p>A restraint order can be varied or discharged upon application by a person affected by the order. The Proceeds of Crime Act also provides that the court is required to discharge any restraint order at the conclusion of proceedings. If an order is made under condition (1) above, the court is also required to monitor progress with the investigation, and if a decision to charge is not made within a reasonable time, the court may discharge the restraint order.</p> answering member constituency Hemel Hempstead answering member printed Mike Penning question first answered 16/09/2015 12:20:37 answering member 1528 label Biography information for Sir Mike Penning
tabling member	1538 label Biography information for Rosie Cooper

418048

registered interest
date	09/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the administrative cost was of the Cancer Drugs Fund re-evaluation process in 2014-15.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9754
answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>NHS England has advised that this information is not available given the multi-disciplinary nature of the Cancer Drugs Fund re-evaluation process and the involvement of different parts of the National Health Service.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 08:56:08 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

418049

registered interest
date	09/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with NHS England on how the survival rates for pancreatic cancer are reflected in assessments of new treatments for that disease.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9823
answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>We have had no such discussions.</p><p> </p><p> </p><p> </p><p>NHS England assesses new cancer drugs for inclusion on the national Cancer Drugs Fund (CDF) list in accordance with its CDF Standard Operating Procedures, which are available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/cdf-sop/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/cdf-sop/</a></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 14:43:49 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

417657

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the level of provision of pancreatic cancer treatment on the NHS; and if he will make a statement.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9405
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>Over the last 15 years, services for pancreatic cancer have been significantly strengthened within the National Health Service. This includes clearer diagnostic pathways, decision making by specialist multi-disciplinary teams and centralisation of pancreas surgery within specialist teams.</p><p> </p><p> </p><p> </p><p>Between 1999 and 2009, following reorganisation of pancreas services, there are now twice as many patients accessing surgery, and one year survival has increased by 5%. The benefits of the United Kingdom model are recognised internationally.</p><p> </p><p> </p><p> </p><p>It is recognised that pancreatic cancer is a challenging disease for a number of reasons. There is a lack of any effective drug therapies and research opportunities are restricted by the small number of patients with the disease (approximately 7,000 annually), and the relatively low survival rates.</p><p> </p><p> </p><p> </p><p>Symptoms are variable and difficult to identify, and there is presently no diagnostic test, although a test is in the research phase.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/09/2015 12:25:49 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

417658

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that expert clinicians are consulted when assessing new treatments for pancreatic cancer.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9406
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The National Institute for Health and Care Excellence’s (NICE) guidance is based on a thorough assessment of the available evidence and is developed through wide consultation with stakeholders. NICE makes every effort to ensure that appropriate stakeholders, including clinical experts, are able to engage with the development of its guidance.</p><p> </p><p> </p><p> </p><p>As part of NICE’s technology appraisal process, clinical specialists, commissioning experts and patient experts are invited by the Appraisal Committee to provide written evidence and attend the Committee meeting to help in the Committee's discussion of the technology being appraised.</p><p> </p><p> </p><p> </p><p>NHS England is responsible for administering the Cancer Drugs Fund (CDF) and decisions on which treatments are included on the national CDF list are made by the CDF clinical panel. The panel includes expert oncologists, oncology pharmacists and patient representatives.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:55:39 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

417664

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the reasons are for the most recent NHS England review of the pancreatic cancer drug available on the national Cancer Drugs Fund.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9391
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The Cancer Drugs Fund panel considered a number of drug/indications for reprioritisation in July 2015. The panel’s decisions were announced on 4 September 2015 and are available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/cdf-drug-sum/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/cdf-drug-sum/</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:57:19 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

391685

registered interest
date	21/07/2015
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Electronic Commerce
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, if he will bring forward regulations to clarify the legal protections that third party companies receive with regard to stock and stock lists which are held by online retailers; and if he will make a statement.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	8232
answer	answer is ministerial correction date of answer 07/09/2015 answer text <p>No, given the rights and obligations of businesses holding stock on behalf of third parties are well-established and in the event of a dispute it is for the courts to determine the outcome, based on the facts of the case.</p><p> </p> answering member constituency Broxtowe answering member printed Anna Soubry question first answered 07/09/2015 08:42:37 answering member 3938 label Biography information for Anna Soubry
tabling member	1538 label Biography information for Rosie Cooper

391824

registered interest
date	21/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS England
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether NHS England has a responsibility formally to respond to requests from NHS trusts to undertake joint investigations into serious incidents.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	8234
answer	answer is ministerial correction date of answer 07/09/2015 answer text <p>There is no formal requirement for NHS England to respond to requests from organisations to undertake joint investigations. However, NHS England regional teams are able to provide advice and/or support in order to assist the incident management and investigation process, particularly in complex situations where multiple organisations (including NHS providers and commissioning organisations) are involved. In such circumstances NHS England may, for example, facilitate discussions relating to who is the most appropriate organisation to take responsibility for co-ordinating the investigation process. Or, where no one provider or commissioning organisation is best placed to assume this responsibility, NHS England may agree to lead this process.</p><p> </p><p> </p><p> </p><p>In relation to the Lancashire Care NHS Foundation Trust, enquires have been made with the Trust and local clinical commissioning group (CCG) and neither are able to find any intelligence in relation to a request for a joint investigation.</p><p> </p><p> </p><p> </p><p>The only incidents that would potentially be investigated by NHS England are those identified in the Serious Incident Framework i.e. independent investigations and NHS England’s role in the Serious Incident Framework is that of a commissioner for directly commissioned services to maintain oversight and surveillance of serious incident management and assures that CCGs have systems in place to manage investigations appropriately.</p><p> </p><p> </p><p> </p><p>The revised Serious Incident Framework (published March 2015) provides details relating to the roles and responsibilities of NHS England with regards to management serious incidents. The framework is available online at:</p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/patientsafety/serious-incident/" target="_blank">http://www.england.nhs.uk/ourwork/patientsafety/serious-incident/</a> (please refer to Part 2: Section 2 and 3 for supplementary guidance). As stated within the Serious Incident Framework, NHS England’s involvement would need to be considered and agreed on a case by case basis, depending on the circumstances of the incident and with a view to ensuring that learning from serious incidents is maximised to prevent recurrence of future harm.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Ipswich answering member printed Ben Gummer grouped question UIN 8233 question first answered 07/09/2015 15:10:23 answering member 3988 label Biography information for Ben Gummer
tabling member	1538 label Biography information for Rosie Cooper